Work

Cost-effectiveness analysis of tarlatamab as second-line therapy for small-cell lung cancer after platinum-based chemotherapy

Year: 2026

Type: article

Source: Immunotherapy

DOI: 10.1080/1750743x.2026.2758055

Authors: Zhengxiong Li, Jiaming Zhu, Kai Ma

Institutions: Xuzhou Medical College, Zhejiang Chinese Medical University

Language: English

Topic: Health Systems, Economic Evaluations, Quality of Life

Subfield: Economics and Econometrics

Field: Economics, Econometrics and Finance

Domain: Social Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7225657296

FWCI:

Cites: 38

Cited by:

Related to: 10